Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 44: 10-11, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tuchman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuchman, M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 1998;44:10-11.)
© 1998 American Association for Clinical Chemistry, Inc.


Editorial

Molecular Diagnosis of Medium-Chain Acyl-CoA Dehydrogenase Deficiency by Oligonucleotide Ligation Assay

Mendel Tuchmana

Departments of Pediatrics and, Laboratory Medicine and Pathology, University of Minnesota Medical School, Box 400, 420 Delaware St. SE, Minneapolis, MN 55455, Fax 612-624-2682, E-mail tuchm001@maroon.tc.umn.edu
a Address for correspondence.

In the current issue of Clinical Chemistry, Romppanen et al. (1) report a molecular screening study in a Finnish population for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, the most common inherited disorder of fatty acid ß-oxidation (2). This metabolic disorder, which is transmitted as an autosomal recessive trait, can be regarded as a paradigm for inborn errors of metabolism. As seen in many other genetic disorders, a phenotypic heterogeneity frequently is expressed within the same family, ranging from sudden infant death to asymptomatic individuals (3). The disorder is one of exacerbations and remissions and was initially recognized in children with hypoketogenic hypoglycemia, Reye syndrome, and (or) liver failure, frequently resulting in severe brain damage (2). The pathophysiology of MCAD deficiency involves the inability of cells to oxidize fatty acids 4–12 carbons long. A secondary effect of the metabolic block is systemic carnitine deficiency, further compromising fatty acid metabolism. Thus, clinical attacks are precipitated during fasting or intercurrent illnesses when fat mobilization and fatty acid oxidation are induced. Biochemical markers that are diagnostic of MCAD deficiency include urine hexanoylglycine and phenylpropionylglycine (4) and plasma and urine octanoylcarnitine (5).

If the disease is recognized before severe sequelae ensue, conservative treatment results in an excellent prognosis. Therapy involves anticipation and prevention of metabolic decompensation by administration of glucose-containing fluids and L-carnitine. This treatment during an impending catabolic crisis prevents the combination of severe hypoglycemia, dehydration, and metabolic acidosis that might . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
E.-L. Romppanen and I. Mononen
PCR-Oligonucleotide Ligation Assay from Dried Blood Spots
Clin. Chem., November 1, 1999; 45(11): 2022 - 2025.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.